Polymer-drug conjugates as modulators of cellular apoptosis

AAPS Journal

Volumn 9, Issue 2, 2007, Pages

  Vicent, María J ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Apoptosis modulators; Polymer drug conjugates; Targeted delivery

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; COPPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MACROGOL ARGINYLGLYCYLASPARTIC ACID CO 64 CONJUGATE; CT 2106; CYCLODEXTRIN CAMPTOTHECIN CONJUGATE; CYTOKINE; DOXORUBICIN; EZ 246; FCE 28068; FUMAGILLOL CHLOROACETYLCARBAMATE; IODINE MACROGOL ARGINYLGLYCYLASPARTIC ACID 1 125 CONJUGATE; MACROGOL; MACROGOL AMINOADIPIC ACID EPIRUBICIN NITRIC OXIDE CONJUGATE; MACROGOL CAMPTOTHECIN BH3 PROTEIN CONJUGATE; MACROGOL CAMPTOTHECIN CONJUGATE; MACROGOL CAMPTOTHECIN GONADORELIN RECEPTOR CONJUGATE; MACROGOL PEPTOID CONJUGATE; MACROGOL PROTOPORPHYRIN ZINC CONJUGATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER AMINOGLUTETHIMIDE DOXORUBICIN CONJUGATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE DOXORUBICIN CONJUGATE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PK 1; POLYGLUTAMIC ACID; POLYGLUTAMIC ACID CAMPTOTHECIN CONJUGATE; POLYGLUTAMIC ACID PACLITAXEL CONJUGATE; POLYMER; POLYSACCHARIDE; PROTEIN DERIVATIVE; T 101; TECHNETIUM N (2 HYDROXYPROPYL)METHACRYLAMIDE ARGINYLGLYCYLASPARTIC ACID 4C TC 993 CONJUGATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CLINICAL TRIAL; CONSENSUS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; HORMONAL THERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; REVIEW; SOLID TUMOR;

APOPTOSIS; DRUG CARRIERS; HUMANS; ISCHEMIA; MOLECULAR STRUCTURE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 34347207622     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0902022     Document Type: Review

References (78)

1. Duncan R. Polymer-drug conjugates. In: Budman D, Calvert H, Rowinsky E, eds. Handbook of Anticancer Drug Development. Baltimore, MD: Lippincott Williams & Wilkins;2003:239-260.
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-6392.
3. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6:688-701.
4. Satchi-Fainaro R, Duncan R, Barnes CM. Polymer therapeutics for cancer: current status and future challenges. Adv Polym Sci. 2006; 193:1-65.
5. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006;24:39-47.
6. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci. 2006;31:359-397.
7. Alam JJ. Apoptosis: target for novel drugs. Trends Biotechnol. 2003;21:479-483.
8. Sausville EA, Elsayed Y, Monga M, Kim G. Signal transduction; directed cancer treatments. Annu Rev Pharmacol Toxicol. 2003;43:199-231.
9. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew Chem Int Ed Engl. 2005;44:4061-4066.
10. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov. 2002;1:111-121.
11. Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest. 2005;115:2610-2617.
12. Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;121:671-674.
13. Spierings D, McStay G, Saleh M, et al. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science. 2005;310:66-67.
14. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-245.
15. Zou H, Li YC, Liu HS, Wang XD. An APAF-1 center dot cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549-11556.
16. Chai JJ, Du CY, Wu JW, Kyin S, Wang XD, Shi YG. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000;406:855-862.
17. Hao ZY, Duncan GS, Chang CC, et al. Specific ablation of the apoptotic functions of cytochrome c reveals a differential requirement for cytochrome c and apaf-1 in apoptosis. Cell. 2005;121:579-591.
18. Riedl SJ, Li WY, Chao Y, Schwarzenbacher R, Shi YG. Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature. 2005;434:926-933.
19. Chereau D, Zou H, Spada AP, Wu JC. A nucleotide binding site in caspase-9 regulates apoptosome activation. Biochemistry. 2005;44:4971-4976.
20. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42-49.
21. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin: fi rst member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res. 1999;5:83-94.
22. Minko T, Kopeckova P, Kopecek J. Mechanisms of anticancer action of HPMA copolymer-bound doxorubicin. Macromol Symp. 2001;172:35-48.
23. Kovar M, Mrkvan T, Strohalm J, et al. HPMA copolymer-bound doxorubicin targeted to tumor-specifi c antigen of BCL1 mouse B cell leukemia. J Control Release. 2003;92:315-330.
24. Rihova B, Strohalm J, Kubackova K, et al. Acquired and specific immunological mechanism co-responsible for effi cacy of polymer-bound drugs. J Control Release. 2002;78:97-114.
25. Rihova B, Strohalm J, Prausova J, et al. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J Control Release. 2003;91:1-16.
26. Duncan R. N-(2-hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon GS, ed. Polymeric Drug Delivery Systems. New York, NY: Marcel Dekker, Inc; 2005:1-92.
27. Li C, Yu DF, Newman R, et al. Complete regression of well-established tumors using novel water-soluable poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998;58:2404-2409.
28. Singer JW. Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular taxane. J Control Release. 2005;109:120-126.
29. Ross H, Bonomi P, Langer C. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive patients with advanced NSCLC and poor performance status (PS2) [abstract]. Clin Oncol. 2006;97:.
30. O'Brien M, Bonomi P, Langer C. Analysis of prognostic factors in chemo-naive patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials [abstract]. Clin Oncol. 2006;97:.
31. Oldham EA, Li C, Ke S, Wallace S, Huang P. Comparison of action of paclitaxel and poly(L-glutamic acid)paclitaxel conjugate in human breast cancer cells. Int J Oncol. 2000;16:125-132.
32. Bhatt R, de Vries P, Tulinsky J, et al. Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin. J Med Chem. 2003;46:190-193.
33. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase-I inhibition by camptothecin - evidence for binding to an enzyme DNA complex. Biochemistry. 1989;28:4629-4638.
34. Posey JA, Saif MW, Carlisle R, et al. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2005;11:7866-7871.
35. Schluep T, Hwang J, Cheng JJ, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006;12:1606-1614.
36. Zamboni WC, Goel S, Iqbal T, et al. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chem Pharmacol. 2006;57:631-639.
37. Schluep T, Cheng JJ, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chem Pharmacol. 2006;57:654-662.
38. Minko T, Paranjpe PV, Qiu B, et al. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chem Pharmacol. 2002;50:143-150.
39. Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release. 2003;91:61-73.
40. Dharap SS, Wang Y, Chandna P, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA. 2005;102:12962-12967.
41. Kabanov AV. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev. 2006; 58:1597-1621.
42. Fiebig HH, Burger AM. Target-directed in vitro and in vivo testing procedures for the discovery of anticancer agents. Clin Cancer Res. 1999;5:S3870-S3870.
43. Eskens F, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006;42:3127-3139.
44. Lippert JW, III. Vascular disrupting agents. Bioorg Med Chem. 2007;15:605-615.
45. Dayam R, Grande F, Al-Mawsawi LQ, Neamati N. Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opin Ther Pat. 2007;17:83-102.
46. Satchi-Fainaro R, Puder M, Davies JW, et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med. 2004;10:255-261.
47. Huang JZ, Frischer JS, New T, et al. TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther. 2004;3:335-343.
48. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res. 2003;9:886-899.
49. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PEG. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res. 2003;9:355-362.
50. Mitra A, Nan A, Papadimitriou JC, Ghandehari H, Line BR. Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol. 2006;33:43-52.
51. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: Cu-64 labeling and PET imaging of brain tumor alpha(v)beta(3)-integrin expression. J Nucl Med. 2004;45:1776-1783.
52. Chen X, Park R, Hou Y, et al. MicroPET and autoradiographic imaging of GRP receptor expression with Cu-64-DOTA-Lys(3) bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
53. Juin P, Geneste O, Raimbaud E, Hickman JA. Shooting at survivors: Bcl-2 family members as drug targets for cancer. Biochim Biophys Acta. 2004;1644:251-260.
54. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2:347-360.
55. Oman M, Liu JH, Chen J, et al. Using N-(2-hydroxypropyl) methacrylamide copolymer drug bioconjugate as a novel approach to deliver a Bcl-2-targeting compound HA14-1 in vivo. Gene Ther Mol Biol. 2006;10A:113-122.
56. Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res. 2002;62:3138-3143.
57. Fang J, Sawa T, Maeda H. Factors and Mechanism of "EPR" Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS Book Series Advances in Experimental Medicine and Biology. In: Maeda H, Kabanov A, Kataoka K, Okano T, eds. Polymer Drugs in the Clinical Stage. Dordrecht, The Netherlands: SpringerLink Netherlands; 2004:29-49.
58. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target in anticancer treatment. Apoptosis. 2004;9:27-35.
59. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer. 2004;109:1-8.
60. Sahoo SK, Sawa T, Fang J, et al. Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjugate Chem. 2002;13:1031-1038.
61. Fang J, Sawa T, Akaike T, et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 2003;63:3567-3574.
62. Herzog T, Barret RJ, Edwards R, Oldham FB. Phase II study of paclitaxel poliglumex (PPX)/carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma. J Clin Oncol. 2005;23:16S.
63. Greco F, Vicent MJ, Gee S, et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release. 2007;117:28-39.
64. Santucci L, Mencarelli A, Renga B, et al. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J. 2006;20:765-775.
65. Khandare JJ, Chandna P, Wang Y, Pozharov VP, Minko T. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther. 2006;317:929-937.
66. Pasut G, Mero A, Bertuglia S, Veronese FM. Novel PEG conjugates releasing nitric oxide: preparation and activity against oxidative stress in ischemia reperfusion injury. Paper presented at: 33rd Annual Meeting & Expo of the Controlled Release Society; June 21-26, 2006; Vienna, Austria.
67. Acehan D, Jiang XJ, Morgan DG, Heuser JE, Wang XD, Akey CW. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell. 2002;9:423-432.
68. Lademann U, Cain K, Gyrd-Hansen M, Brown D, Peters D, Jaattela M. Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. Mol Cell Biol. 2003;23:7829-7837.
69. Malet G, Martín AG, Orzáez M, et al. Small molecule inhibitors of Apaf-1-related caspase-3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ. 2006;13:1523-1532.
70. Vicent MJ, Pérez-Payá E. Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J Med Chem. 2006;49:3763-3765.
71. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: "addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8:183-197.
72. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.
73. Audran M. Drug combination strategies for osteoporosis. Joint Bone Spine. 2006;73:374-378.
74. Balan V, Rosati MJ, Anderson MH, Rakela J. Successful treatment with novel triple drug combination consisting of interferongamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. Dig Dis Sci. 2006; 51:956-959.
75. Blank-Porat D, Nudelman A, Berkovitch G, Malik Z, Rephaeli A. In vitro drug combination investigation could assist clinical study design. Clin Cancer Res. 2005;11:8988S.
76. Gupta M, Robinson B, Felix C, Barrett J. Strategies for assessment of drug combination therapy: response surface modeling of MTT assays to assess target agent synergy via cell survival. J Clin Pharmacol. 2005;45:1093.
77. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl. 2006;45:1198-1215.
78. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and relevance in cancer. Ann Hematol. 2005;84:627-639.